Canaccord Genuity Maintains Buy on Fractyl Health, Lowers Price Target to $39

Canaccord Genuity analyst Whitney Ijem has maintained a Buy rating on Fractyl Health (NASDAQ: GUTS) but has reduced the price target from $96 to $39.